Polycystic ovarian syndrome - Pipeline Insight, 2024

This “Polycystic ovarian syndrome - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 7+ pipeline drugs in Polycystic ovarian syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Polycystic ovarian syndrome: Understanding

Polycystic ovarian syndrome Overview

Polycystic ovarian syndrome (PCOS) is the most common endocrine pathology in females of reproductive worldwide. Stein and Leventhal initially described it in 1935. The prevalence ranges between 5% and 15% depending on the diagnostic criteria applied. It is widely accepted among specialty society guidelines that the diagnosis of PCOS must be based on the presence of at least two of the following three criteria: chronic anovulation, hyperandrogenism (clinical or biological), and polycystic ovaries. It is a diagnosis of exclusion, and disorders that mimic clinical features of PCOS must be excluded. These include thyroid disease, hyperprolactinemia, and non-classical congenital adrenal hyperplasia. Selected patients may need more extensive workup if clinical features suggest other causes.

Despite its high prevalence, PCOS is underdiagnosed and frequently takes more than one visit or different physicians to get identified, and these usually occur in more than a one-year timeframe. It is a very frustrating process for the patient. Delay in diagnosis can lead to the progression of comorbidities making it more difficult to implement lifestyle intervention, which is critical for the improvement of features of PCOS and quality of life.

Polycystic ovarian syndrome- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polycystic ovarian syndrome pipeline landscape is provided which includes the disease overview and Polycystic ovarian syndrome treatment guidelines. The assessment part of the report embraces, in depth Polycystic ovarian syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence in Polycystic ovarian syndrome R&D. The therapies under development are focused on novel approaches to treat/improve in Polycystic ovarian syndrome.

This segment of the Polycystic ovarian syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Polycystic ovarian syndrome Emerging Drugs

DLBS3233: Dexa Medica Trofinetide is an investigational drug. It is a novel synthetic analog of the amino-terminal tripeptide of IGF-1 designed to treat the core symptoms of Polycystic ovarian syndrome by potentially reducing neuroinflammation and supporting synaptic function. Trofinetide is thought to stimulate synaptic maturation and overcome the synaptic and neuronal immaturities that are characteristic of Polycystic ovarian syndrome pathophysiology. In the central nervous system, IGF-1 is produced by both of the major types of brain cells - neurons and glia. IGF-1 in the brain is critical for both normal development and for response to injury and disease. Trofinetide has been shown to inhibit the production of inflammatory cytokines, inhibit the overactivation of microglia and astrocytes, and increase the amount of available IGF-1 that can bind to IGF-1receptors.

Polycystic ovarian syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Polycystic ovarian syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Polycystic ovarian syndrome

There are approx. 5+ key companies which are developing the therapies for Polycystic ovarian syndrome. The companies which have their Polycystic ovarian syndrome drug candidates in the most advanced stage, i.e. Phase III include, Dexa Medica.

Phases

This report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Polycystic ovarian syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

Molecule Type

Products have been categorized under various Molecule types such as

• Peptide
• Protein
• Propylene glycols
• Cell Therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Polycystic ovarian syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polycystic ovarian syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polycystic ovarian syndrome drugs.

Polycystic ovarian syndrome Report Insights

• Polycystic ovarian syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Polycystic ovarian syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Polycystic ovarian syndrome drugs?
• How many Polycystic ovarian syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polycystic ovarian syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Polycystic ovarian syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Polycystic ovarian syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Dexa Medica Group
• AbbVie
• Kindex Pharmaceuticals
• Spruce Biosciences
• Bioresearch
• Forendo Pharma
• Cadila healthcare

Key Products

• DLBS3233
• Elagolix
• KDT 501
• Tildacerfont
• HSD17B5 inhibitor

This product will be delivered within 2 business days.